BTIG Assumes Lyra Therapeutics at Buy, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin has assumed Lyra Therapeutics (NASDAQ:LYRA) with a Buy rating and announced a price target of $15.
October 06, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lyra Therapeutics has been assumed with a Buy rating by BTIG analyst Justin Zelin, who has set a price target of $15.
The Buy rating and price target set by BTIG analyst Justin Zelin indicates a positive outlook for Lyra Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100